-
Patent Agency Ranking
公开(公告)号：US07842707B2
公开(公告)日：2010-11-30
申请号：US11571857
申请日：2005-07-21
Applicant: Susan Marie Royalty , James Ford Burns , Jan Jozef Scicinski , Gunnar Erik Jagdmann, Jr. , Robert James Foglesong , Kellee Griffin Ring , Tatyana Dyakonov , David Middlemiss
Inventor： Susan Marie Royalty , James Ford Burns , Jan Jozef Scicinski , Gunnar Erik Jagdmann, Jr. , Robert James Foglesong , Kellee Griffin Ring , Tatyana Dyakonov , David Middlemiss
IPC: A01N43/40 , A01N43/78 , A01N43/80 , A01N43/36 , A61K31/44 , A61K31/425 , A61K31/42 , A61K31/40 , C07D401/00 , C07D277/00 , C07D261/00 , C07D295/00
CPC classification number: C07D207/10 , C07D207/16 , C07D277/04 , C07D401/12 , C07D403/12 , C07D405/12
Abstract: The present invention relates to a series of novel compounds having the formula (I) wherein: X is NR3 or O; n is 1 or 2; A is a bicyclic carbocycle and R1 and R2 are as described herein. The compounds are useful as DPP-IV inhibitors, such as for the treatment of diabetes.
Abstract translation: 本发明涉及一系列具有式（I）的新化合物，其中：X为NR 3或O; n为1或2; A是双环碳环，R 1和R 2如本文所述。 该化合物可用作DPP-IV抑制剂，例如治疗糖尿病。
-
公开(公告)号：US20080234292A1
公开(公告)日：2008-09-25
申请号：US11571857
申请日：2005-07-21
Applicant: Susan Marie Royalty , James Ford Burns , Jan Jozef Scicinski , Gunnar Erik Jagdmann, Jr. , Robert James Foglesong , Kellee Griffin Ring , Tatyana Dyakonov , David Middlemiss
Inventor： Susan Marie Royalty , James Ford Burns , Jan Jozef Scicinski , Gunnar Erik Jagdmann, Jr. , Robert James Foglesong , Kellee Griffin Ring , Tatyana Dyakonov , David Middlemiss
IPC: A61K31/40 , C07D207/16 , C07D401/12 , C07D403/12 , C07D413/12 , C07D277/04 , A61K31/497 , A61K31/506 , A61K31/4439 , A61K31/426 , A61K31/422 , A61P3/10
CPC classification number: C07D207/10 , C07D207/16 , C07D277/04 , C07D401/12 , C07D403/12 , C07D405/12
Abstract: The present invention relates to a series of novel compounds having the formula (I) wherein: X is NR3 or O; n is 1 or 2; A is a bicyclic carbocycle and R1 and R2 are as described herein. The compounds are useful as DPP-IV inhibitors, such as for the treatment of diabetes.
Abstract translation: 本发明涉及一系列具有式（I）的新化合物，其中：X为NR 3或O; n为1或2; A是双环碳环，R 1和R 2如本文所述。 该化合物可用作DPP-IV抑制剂，例如治疗糖尿病。
-
公开(公告)号：US20120129806A1
公开(公告)日：2012-05-24
申请号：US13276806
申请日：2011-10-19
Applicant: Michael Van Zandt , Gunnar Erik Jagdmann, JR.
Inventor： Michael Van Zandt , Gunnar Erik Jagdmann, JR.
Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
Abstract translation: 根据式I的化合物是精氨酸酶I和II活性的有效抑制剂：其中R1，R2，R3，R4，D，W，X，Y和Z在本说明书中定义。 本发明还提供了化合物的药物组合物及其用于治疗或预防与精氨酸酶活性相关的疾病或病症的方法。
-
公开(公告)号：US06800651B2
公开(公告)日：2004-10-05
申请号：US10182961
申请日：2002-11-20
Applicant: Darrell Stephen Coleman , Gunnar Erik Jagdmann , Kirk Willis Johnson , Michael Parvin Johnson , Thomas Hallett Large , James Allen Monn , Darryle Darwin Schoepp , Thomas Charles Britton , Steven Scott Henry , Joseph Patrick Tizzano
Inventor： Darrell Stephen Coleman , Gunnar Erik Jagdmann , Kirk Willis Johnson , Michael Parvin Johnson , Thomas Hallett Large , James Allen Monn , Darryle Darwin Schoepp , Thomas Charles Britton , Steven Scott Henry , Joseph Patrick Tizzano
IPC: A01K3144
CPC classification number: C07D213/40 , C07D213/30 , C07D213/38 , C07D213/42 , C07D213/61 , C07D213/643 , C07D213/76 , C07D213/89 , C07D405/12 , C07D409/12
Abstract: The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.
-
公开(公告)号：US09233985B2
公开(公告)日：2016-01-12
申请号：US13276806
申请日：2011-10-19
Applicant: Michael Van Zandt , Gunnar Erik Jagdmann, Jr.
Inventor： Michael Van Zandt , Gunnar Erik Jagdmann, Jr.
Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
Abstract translation: 根据式I的化合物是精氨酸酶I和II活性的有效抑制剂：其中R1，R2，R3，R4，D，W，X，Y和Z在本说明书中定义。 本发明还提供了化合物的药物组合物及其用于治疗或预防与精氨酸酶活性相关的疾病或病症的方法。
-
-
-
-
Search Results
5
records
(took 0.021 seconds)
